Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
TransMedics Group Inc (TMDX)
NASDAQ:TMDX
Holding TMDX?
Track your performance easily
TMDX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$56.83 - $177.37
Previous Close$89.11
Volume1.67M
Average Volume (3M)1.39M
Market Cap
$2.99B
Enterprise Value$3.18B
Total Cash (Recent Filing)$330.10M
Total Debt (Recent Filing)$518.15M
Price to Earnings (P/E)95.5
Beta1.74
Next Earnings
Mar 04, 2025EPS Estimate
$0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.93
Shares Outstanding33,561,517
10 Day Avg. Volume1,858,972
30 Day Avg. Volume1,392,237
Standard Deviation0.26
R-Squared0.17
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)14.63
Price to Sales (P/S)7.46
Price to Cash Flow (P/CF)109.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.93
Enterprise Value/Gross Profit20.63
Enterprise Value/Ebitda51.97
Forecast
1Y Price Target
$131.38Price Target Upside43.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
TransMedics Group News
Bulls Say, Bears Say
Bulls Say
Market LeadershipTMDX remains the market leader in a still very underpenetrated market, with confidence in launching OCS Heart and Lung clinical programs that could drive further adoption.
Revenue GrowthTransMedics maintained its FY24 guidance, still projecting significant revenue growth, with product growth indicating strength despite the overall sales miss.
Share Gain MomentumDespite challenges, TMDX sustained its share gain momentum and will deliver sequential revenue growth, suggesting the offering continues to gain share in the DCD heart and liver organ preservation markets.
Bears Say
Financial PerformanceTransMedics reported Q3 revenue of $108.8M, missing the $118.6M estimate and consensus of $115.0M.
Market ShareThe company's share in the transplant market was stable, which could be concerning as TransMedics has been a growth name taking market share.
Operational ChallengesRevenue growth slowed to 64% in 3Q24 from 118% in 2Q24 as TMDX saw headwinds from slower transplant market volumes and a decreased fleet capacity due to maintenance.
---
Ownership Overview
3.35% Insiders
39.01% Mutual Funds
8.11% Other Institutional Investors
24.19% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TMDX FAQ
What was TransMedics Group Inc’s price range in the past 12 months?
TransMedics Group Inc lowest stock price was $56.83 and its highest was $177.37 in the past 12 months.
What is TransMedics Group Inc’s market cap?
Currently, no data Available
When is TransMedics Group Inc’s upcoming earnings report date?
TransMedics Group Inc’s upcoming earnings report date is Mar 04, 2025 which is in 103 days.
How were TransMedics Group Inc’s earnings last quarter?
TransMedics Group Inc released its earnings results on Oct 28, 2024. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.293 by -$0.173.
Is TransMedics Group Inc overvalued?
According to Wall Street analysts TransMedics Group Inc’s price is currently Undervalued.
Does TransMedics Group Inc pay dividends?
TransMedics Group Inc does not currently pay dividends.
What is TransMedics Group Inc’s EPS estimate?
TransMedics Group Inc’s EPS estimate is $0.21.
How many shares outstanding does TransMedics Group Inc have?
TransMedics Group Inc has 33,561,516 shares outstanding.
What happened to TransMedics Group Inc’s price movement after its last earnings report?
TransMedics Group Inc reported an EPS of $0.12 in its last earnings report, missing expectations of $0.293. Following the earnings report the stock price went down -29.895%.
Which hedge fund is a major shareholder of TransMedics Group Inc?
Among the largest hedge funds holding TransMedics Group Inc’s share is Driehaus Capital Management LLC. It holds TransMedics Group Inc’s shares valued at 224M.
---
TransMedics Group Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$131.38 (43.73% Upside)
$131.38 (43.73% Upside)
Blogger Sentiment
Bullish
TMDX Sentiment 88%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 188.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $9.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 17.0%
Last 30 Days ▲ 17.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
55.32%
12-Months-Change
Fundamentals
Return on Equity
19.41%
Trailing 12-Months
Asset Growth
13.98%
Trailing 12-Months
Company Description
TransMedics Group Inc
TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.
---
TMDX Earnings Call
Q3 2024
0:00 / 0:00
---
TMDX Stock 12 Month Forecast
Average Price Target
$131.38
▲(43.73% Upside)
Technical Analysis
Best Analysts Covering TMDX
1 Year
1 Year Success Rate
19/24 ratings generated profit
1 Year Average Return
+41.20%
reiterated a buy rating 24 days ago
Copying Suraj Kalia's trades and holding each position for 1 Year would result in 79.17% of your transactions generating a profit, with an average return of +41.20% per trade.
---